CONGRESS FOR VOTERS

RepublicanBill · S. 5059· Senate(119-S-5059)

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

Rep. Moody
Age: 51 years
Florida
Introduced
7/21/2026
Last activity
7/21/2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by
Ashley Moody
Cosponsors
Republican - 1Democrat - 2
Health
  1. Introduced
  2. In Committee

What this bill would do

This bill seeks to amend the Public Health Service Act. The specific goal is to streamline the review process for biosimilar biological products. To achieve this, the legislation proposes changes to Section 351(k)(5) of the Act. The amendment involves striking a specific subparagraph and redesignating another. This action is intended to modify how these products are reviewed.

Yes· 3 of 6

  • Does this lower the price of prescription medicines?+3

    The bill streamlines the review process for biosimilars, which can increase competition and lower drug prices.

  • Would people over 65 be better off under this?+2

    Streamlined biosimilar reviews may lower costs for medications often used by older populations.

  • Would households on low incomes be better off under this?+2

    Increased competition from biosimilars may reduce the cost of essential biological medicines.

The opposite

No question was scored the opposite.